1. Home
  2. CTNM vs NGS Comparison

CTNM vs NGS Comparison

Compare CTNM & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$14.38

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Logo Natural Gas Services Group Inc.

NGS

Natural Gas Services Group Inc.

HOLD

Current Price

$35.53

Market Cap

558.5M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTNM
NGS
Founded
2009
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
550.7M
558.5M
IPO Year
2024
2006

Fundamental Metrics

Financial Performance
Metric
CTNM
NGS
Price
$14.38
$35.53
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$19.00
$40.67
AVG Volume (30 Days)
266.2K
107.8K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
1.08%
EPS Growth
0.46
14.60
EPS
N/A
0.53
Revenue
N/A
$172,315,000.00
Revenue This Year
N/A
$15.05
Revenue Next Year
N/A
$9.52
P/E Ratio
N/A
$67.19
Revenue Growth
N/A
9.94
52 Week Low
$5.08
$22.72
52 Week High
$16.91
$44.61

Technical Indicators

Market Signals
Indicator
CTNM
NGS
Relative Strength Index (RSI) 50.66 32.12
Support Level $13.62 $32.52
Resistance Level $15.00 $35.35
Average True Range (ATR) 0.88 2.10
MACD -0.12 -0.46
Stochastic Oscillator 40.31 7.62

Price Performance

Historical Comparison
CTNM
NGS

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About NGS Natural Gas Services Group Inc.

Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. It operates in one reporting segment. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.

Share on Social Networks: